Core Viewpoint - Aktis Oncology, Inc. has received FDA clearance for its IND applications to proceed with a Phase 1b clinical trial for AKY-2519, a miniprotein radioconjugate targeting B7-H3, expanding its pipeline of targeted radiopharmaceuticals aimed at treating various solid tumors [1][5]. Company Updates - Aktis Oncology is focused on developing targeted radiopharmaceuticals for prevalent tumor types, with significant progress in clinical trials for its lead product, AKY-1189, which targets Nectin-4 and has received FDA Fast Track designation [2][4]. - The company has a strong cash position, with $226.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which increased to approximately $562.1 million post-IPO [13]. - Collaboration revenue rose to $6.5 million in 2025, up from $1.5 million in 2024, attributed to a partnership with Eli Lilly and Company [13]. Pipeline and Clinical Trials - AKY-1189 is currently in a Phase 1b clinical trial for multiple cancer types, including locally advanced or metastatic urothelial cancer, breast cancer, and non-small cell lung cancer [3][12]. - The anticipated initiation of the Phase 1b clinical trial for AKY-2519 is expected in mid-2026, following the completion of imaging and dosimetry assessments [8][9]. - Preliminary data from the ongoing Phase 1b trial of AKY-1189 is expected in the first quarter of 2027 [9]. Financial Results - For the year ended December 31, 2025, the company reported a net loss of $63.7 million, an increase from $44.0 million in 2024, primarily due to higher R&D expenses [13]. - Research and development expenses increased to $67.5 million in 2025 from $41.0 million in 2024, driven by the advancement of clinical trials for AKY-1189 and AKY-2519 [13].

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai on March 19-20, 2026 [1][2] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (Lu) or Lead-203 (Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with Lu can predict behavior with the therapeutic isotope Actinium-225 (Ac) [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner [3] - This feature enables the selection of the most suitable therapeutic isotope based on initial clinical data without restarting the entire drug discovery process, which is a significant advantage for tailoring treatments to patient needs [3] Group 3: Clinical Trials and Collaborations - The DLL3-targeted Pb-based Radio-DARPin candidate MP0712 is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, covering activities for Radio-DARPins with Ac as the therapeutic payload and Lu as the imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions, addressing limitations of traditional radioligand therapy such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while preserving the advantages of small protein formats, thus unlocking a broad range of tumor targets for targeted radiopharmaceuticals [7] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address, with proprietary programs in various stages of development [10]

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai [1][4] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (177Lu) and Lead-203 (203Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with 177Lu can predict behavior with the therapeutic isotope Actinium-225 (225Ac) and similarly for 203Pb with 212Pb [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner, which can be tailored to patient needs without restarting the drug development process [3] Group 3: Clinical Trials and Partnerships - The MP0712 candidate, which targets DLL3 and is co-developed with Orano Med, is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, focusing on 225Ac as a therapeutic payload and 177Lu as an imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes precisely to tumor lesions, addressing limitations of traditional radioligand therapy, such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while minimizing harm to healthy tissues, leveraging the unique properties of DARPins [9] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for challenging medical conditions, with proprietary programs in various stages of development and partnerships with leading pharmaceutical companies [10]

Core Insights - Molecular Partners AG has entered into a partnership with Eckert & Ziegler to advance its Radio-DARPin therapeutics pipeline, focusing on imaging and therapeutic radio-isotopes, including Actinium-225 [1][2] Group 1: Partnership and Development - The agreement with Eckert & Ziegler will enhance the potential of Radio-DARPins for precise delivery of therapeutic alpha-emitting isotopes to tumors, including Actinium-225 and Lead-212 [2][3] - Eckert & Ziegler will provide a comprehensive range of services for the development of Radio-DARPins with Actinium-225 and Lutetium-177 payloads, utilizing its advanced laboratories [3] Group 2: Pipeline and Research - Molecular Partners is evaluating various radio-nuclides to tailor Radio-DARPin candidates to patient needs, aiming to match vector and isotope properties with target and disease biology [4] - The company plans to present pre-clinical data on the suitability of Radio-DARPins with multiple isotopes at the Global Radiopharmaceuticals Development Summit in March 2026 [4] Group 3: Technology and Innovation - Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions while minimizing toxicity to healthy tissues, addressing historical limitations of radioligand therapy [6][7] - The proprietary Radio-DARPin platform incorporates half-life extension technologies and surface engineering approaches to enhance therapeutic efficacy [6][7] Group 4: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address [9] - The company has proprietary programs in various stages of pre-clinical and clinical development, alongside partnerships with leading pharmaceutical companies and academic centers [9]

Company Overview - Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing technologies [4] - The company's most advanced program, AKY-1189, targets Nectin-4 and has multi-indication potential across various tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer [4] - Aktis' second pipeline program, AKY-2519, targets B7-H3 expressing tumors, including prostate and lung cancers [4] Technology and Innovation - Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors [3] - The therapeutic miniprotein radioconjugates maximize anti-cancer activity through high penetration, internalization, and retention in cancer cells while clearing quickly from normal organs and tissues [3] - The platform allows clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes, addressing unmet needs in solid tumors [3] Upcoming Events - Matthew Roden, Ph.D., President and CEO of Aktis Oncology, will present at the TD Cowen 46 Annual Health Care Conference on March 3, 2026, at 1:10 p.m. ET in Boston, MA [2] - He will also present at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET in Miami, FL [2] - A live webcast of the presentations will be available on the Investors section of the Aktis website, with an archived replay accessible for approximately 90 days [2]

Core Viewpoint - Aktis Oncology, Inc. has received Fast Track designation from the U.S. FDA for its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer who have progressed after prior systemic therapies [1][7] Group 1: Fast Track Designation - Fast Track designation is intended to expedite the development and review of drugs for serious conditions, allowing for more frequent interactions with the FDA and the possibility of rolling submissions for Biologics License Applications [2] - The designation provides Aktis Oncology a unique opportunity to collaborate closely with the FDA to expedite the development of AKY-1189, addressing an unmet medical need in urothelial cancer treatment [3] Group 2: Clinical Trials and Development - Aktis is conducting a multi-site Phase 1b clinical trial (NCT07020117) for AKY-1189, which includes patients with locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors [3] - Preliminary results from Part 1 of the trial are expected to be presented in the first quarter of 2027 [3] Group 3: Technology and Pipeline - Aktis has developed a proprietary miniprotein radioconjugate platform that selectively delivers radioisotopes to targeted tumors, maximizing anti-cancer activity while minimizing exposure to normal tissues [4] - The company’s pipeline includes AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, with potential applications across various tumor types [5]

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Clinical Development - The data from five evaluable patients show favorable tumor uptake of MP0712 with limited uptake in healthy tissues, supporting its therapeutic potential [2][3] - The biodistribution and dosimetry data validate the ongoing U.S. Phase 1/2a study of MP0712, which aims to assess safety and determine a recommended phase 2 dose [4][5] Presentation Details - Two posters and an oral presentation were made at the congress, highlighting the specific tumor accumulation and dosimetry data that support the clinical development of MP0712 [5][7] - The oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was scheduled for January 31, 2026, focusing on the progress of MP0712 [7] Future Outlook - Initial clinical data from the Phase 1/2a study of MP0712 is expected in 2026, with the company planning to share safety and activity data as the study progresses [4][5] - The company aims to establish itself as a leader in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4]

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Group 1: Clinical Development - The data from five evaluable patients support the clinical development plans for MP0712, which utilizes the therapeutic isotope 212Pb [2][4] - The biodistribution of MP0712 shows specific tumor uptake with limited accumulation in healthy tissues, reinforcing its therapeutic potential [3][4] - The ongoing Phase 1/2a study in the U.S. aims to assess safety and determine a recommended phase 2 dose for MP0712, with initial clinical data expected in 2026 [4][5] Group 2: Presentation Details - The data was presented through two posters and an oral presentation at the Theranostics World Congress, highlighting the favorable distribution profile and dosimetry data of MP0712 [2][5] - An oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was conducted, showcasing the progress of MP0712 [7] Group 3: Company Strategy and Future Outlook - The CEO of Molecular Partners expressed optimism about the data, emphasizing the company's ambition to lead in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4] - The company plans to share initial Phase 1 safety and activity data in 2026 as it advances its Radio-DARPin platform [4][5] - Molecular Partners' Radio-DARPins are designed to address limitations of traditional radioligand therapy, enhancing tumor uptake while minimizing toxicity [9][10]